Key result
This text is a journal masthead and contains no clinical study data.
Why the study?
Does primary thromboprophylaxis prevent venous thromboembolism in high-risk cancer patients identified by risk assessment scores?
Population
Cancer patients at risk of developing venous thromboembolism (VTE)
Design
Review
Authors
Loading...
No data to inform thromboprophylaxis in high-risk cancer; leaves open whether risk-score-targeted prevention reduces VTE.
Does primary thromboprophylaxis prevent venous thromboembolism in high-risk cancer patients identified by risk assessment scores?
While VTE risk assessment scores like the Khorana score are feasible and validated in cancer patients, there is a lack of interventional trials evaluating targeted thromboprophylaxis in high-risk groups.
Ay et al. (2012) studied this question. This text is a journal masthead and contains no clinical study data.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: